About Us

Robert DeBenedetto, with backing from Clarus Funds (now Blackstone Life Sciences) and Abingworth Ventures, founded SFJ Pharmaceuticals in 2009.

SFJ’s objective is to provide pharmaceutical and biotech companies incremental budget and global clinical development resources to accelerate the regulatory approval, expand the life cycle and optimize the value of our partners’ most promising pipeline assets. We accomplish this via a unique, risk-based investment model that not only shares the risk of clinical and regulatory success, but also adds incremental indications and markets through resource augmentation.